Previous Close | 11.06 |
Open | 11.65 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's Range | 11.50 - 11.71 |
52 Week Range | 9.07 - 17.05 |
Volume | |
Avg. Volume | 7,017 |
Market Cap | 798.03M |
Beta (5Y Monthly) | 0.88 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.79 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.98 |
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
VALNEVA Declaration of shares and voting rights November 30, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this chan
The announcement ends a lengthy setback that began when the company and partner Valneva accused a clinical trial site operator of study misconduct.
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025Pfizer aims to submit regulatory filings in the U.S. and Europe in 2026 New York, NY, and Saint-Herblain (France), December 4, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that they have